Hologic, Inc. (NASDAQ:HOLX) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC trimmed its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 81.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,295 shares of the medical equipment provider's stock after selling 5,820 shares during the quarter. TD Private Client Wealth LLC's holdings in Hologic were worth $80,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of HOLX. EverSource Wealth Advisors LLC lifted its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Raiffeisen Bank International AG acquired a new position in shares of Hologic in the 4th quarter worth approximately $49,000. West Financial Advisors LLC acquired a new position in shares of Hologic in the 1st quarter worth approximately $50,000. Covestor Ltd lifted its holdings in shares of Hologic by 49.3% in the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock worth $75,000 after acquiring an additional 341 shares during the last quarter. Finally, Transce3nd LLC acquired a new position in shares of Hologic in the 4th quarter worth approximately $96,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Down 1.7%

Shares of NASDAQ:HOLX traded down $1.13 during trading hours on Friday, reaching $65.72. The stock had a trading volume of 1,776,763 shares, compared to its average volume of 2,391,464. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The firm's 50 day moving average is $61.55 and its 200-day moving average is $63.48. The stock has a market capitalization of $14.65 billion, a price-to-earnings ratio of 27.73, a P/E/G ratio of 2.41 and a beta of 0.55. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.03 EPS. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several recent analyst reports. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $60.00 to $80.00 in a report on Wednesday. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Evercore ISI upped their target price on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada cut their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, Morgan Stanley cut their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $78.75.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.